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MGIT 960Abstract Background: Retreatment cases of tuberculosis are reemerging as public and global
health concerns, not only for dissemination of infection but for their multidrug resistant behavior
as well, comprising an important challenge for National Tuberculosis Control Programs. Gene
Xpert MTB/RIF is an automated molecular test for synchronized detection of tuberculosis and
rifampicin resistance, recommended by the World Health Organization. This study was designed
to assess the performance of single-sputum Gene Xpert MTB/RIF assay against the Ziehl–Neelsen
smear, traditional culture and MGIT 960 in diagnosing suspected retreatment pulmonary tubercu-
losis cases and rifampicin resistance.
Subjects and methods: Fifty-eight patients were enrolled in this cross-sectional study from two
Egyptian tertiary care hospitals. The patients were selected fulfilling clinical criteria of suspected
retreatment TB. Early-morning sputum specimens were collected, decontamination liquefaction
technique was done, the specimen was divided into four portions, the first and second portions were
for the Ziehl–Neelsen smear and cultivation on the Lo¨wenstein Jensen media. The third portion was
processed in Gene Xpert MTB/RIF. The fourth part was used for confirmation of rifampicin sus-
ceptibility testing results by MGIT 960.
Results: Gene Xpert MTB/RIF showed sensitivity, specificity and accuracy of 98.15%, 75% and
96.55% respectively in detection of mycobacterium tuberculosis. Regarding rifampicin mono-
resistance, it carried the best sensitivity and specificity of 100% equal to that of reference test MGIT
960.
Conclusion: Gene Xpert MTB/RIF is a sensitive, specific and accurate test for both diagnosis of
retreatment MTB and rifampicin resistance. Finally the authors recommend restandardization of
reference test with Gene Xpert MTB/RIF to obtain more valid results.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
638 T.E. Meawed, A. ShakerIntroduction
As stated by WHO, Egypt is ranked with middle/low level of
tuberculosis (TB) incidence countries, however no available
figure about retreatment TB cases. A multinational study
was carried out under WHO supervision in 2012 comprising
high burden countries, about 6.1 million with TB were notified
to National TB Program. Of these, 0.3 million had a recurrent
episode of TB after treatment and 0.4 million had already been
diagnosed with TB and engaged into a retreatment regimen [1].
Recurrence of active TB after treatment happens either due to
relapse of infection with the same strain or reinfection with a
new strain of mycobacterium TB (MTB). The proportion of
recurrent tuberculosis cases caused by reinfection has varied
widely in previous studies [2]. Yet, retreatment outcomes are
often poor, especially in patients with treatment failure or
default [3]. An alarming rise in the global incidence of infec-
tions caused by MTB has prompted the need for rapid diag-
nostic techniques [4]. Conventional diagnostic methods for
MTB are slow and/or lack sensitivity [5]. Gene Xpert MTB/
RIF assay is an automated, closed-cartridge system, easy to
operate and user friendly. It is based on a hemi nested real-
time PCR assay utilizing five molecular beacon technology
spanning the rpoB gene 81-bp rifampicin resistance-
determining region (RRDR), the test concurrently determines
MTB and rifampin susceptibility, which can be used as aTable 1 Demographic characteristics of all studied patients.
Parameter No %





Ex- smoker 14 24.1
Current smoker 29 50
Presence of comorbidity 23 39.6
Use of corticosteroids 34 58.6











Table 3 Results of culture on LJ medium and Gene Xpert MTB/R
Smear result Results of LJ culture and Gene Xpert
LJ culture +ve and Gene Xpert +ve LJ culture
ZN smear +ve 49 0
ZN smear –ve 5 1surrogate marker for multidrug resistance (MDR–TB) [6].
The results are obtained within a short period of 2 h [4]. This
study was designed to assess the performance of single-sputum
Gene Xpert MTB/RIF assay against the Ziehl–Neelsen smear,
traditional culture and MGIT 960 in diagnosing suspected
retreatment pulmonary tuberculosis cases and rifampicin
resistance (see Tables 1–4).
Study design and setting
A cross sectional study was carried out over one year duration
from November 2014 to October 2015 in both Chest
Department and Medical Microbiological and Immunology
Department, Zagazig University and General Chest Hospital.
The University Ethics Committee approved this study. Full
written consent was taken from all patients enrolled in this
study before history taking or specimen collection.
Patients and methods
This prospective study included 58 suspected (needed to be con-
firmed as retreatment cases bacteriologically) retreatment tuber-
culous outpatients. They asked medical advice at outpatient
clinic of Zagazig University Hospitals and Chest Hospital,
Zagazig, Sharkia Governorate, Egypt, for initial clinical, radio-
logical andmicrobiological assessment and treatment. The diag-
nosis of retreatment pulmonary TB was, as stated by National
TB Control Program of Egypt, [7] on the basis of:
1. History of receiving antituberculous drugs for more than
one month.
2. Recurrence of general and/or local chest symptoms.
3. Documented positive Ziehl–Neelsen (ZN) smear or culture
on the Lowenstein–Jensen (LJ) media for acid- fast bacilli
(AFB) after appearance of symptoms.
Case definition
These retreatment cases include patients with treatment
failure, relapse and defaulters according to Instructions for
completion of the WHO/Euro TB data collection form for
TB cases, 2007 [7].
Treatment failure: is defined as a patient previously treated
for TB but who remained sputum smear positive at five
months or later during treatment.
Relapse: is defined as a patient previously treated for TB
and declared cured or who completed treatment, and was diag-
nosed with sputum smear positive TB.
Defaulter: is defined as a patient previously treated for TB
but who had interrupted treatment for two or more consecu-
tive months.IF regarding to ZN smear.
ve and Gene Xpert +ve LJ culture ve and Gene Xpert ve
0
3
Table 4 Sensitivity and specificity of Gene Xpert MTB/RIF results in comparison to LJ culture results.
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Diagnostic accuracy of Gene Xpert MTB/RIF 639All studied patients were subjected to:
(1) Thorough medical history stressing on general and local
chest symptoms, history of diabetes mellitus (DM),
receiving corticosteroid therapy, associated autoimmune
disorders and history of antituberculous drugs in the
previous course.
(2) Full clinical examination (general and local).
(3) Chest X-ray (Posteroanterior and lateral views) to be
compared with the previous chest X-ray to detect new
radiological data.
(4) Blood chemistry:– Complete blood count (CBC).
– Erythrocyte sedimentation rate (ESR).
– Liver and kidney functions.(5) Microbiology specimen processing:
Early morning spontaneously produced sputum specimens
were taken from all of the studied patients for 3 successive
days, if it was difficult, sputum induction by inhalation of neb-
ulized 5–10% hypertonic saline for 20 min was done [8].
Specimen collection: Early morning sputum was collected
bedside in a sterile screw-capped container with rapid delivery
to the laboratory for fast processing.
All the sputum specimens were subdivided into four por-
tions to be subjected to the following:
I. ZN staining for smear microscopy, smears were repeated
on the next two days.
II. Culture on Lo¨wenstein Jensen (LJ) media: after liquefac-
tion decontamination technique, sputum samples were
cultured on LJ media slopes under 37 C. Culture was
not considered negative except after 8 weeks. Sputum
culture was considered the gold standard technique in
this work.
III. Gene Xpert MTB/RIF PCR test: (Cepheid, Sunnyvale,
CA, USA): according to manufacture instruction, spu-
tum specimens were vortexed for 1 min with glass beads
and split, aliquots were frozen at 70 C to be finally
analyzed by the Xpert MTB/RIF assay, according to
manufacturer’s instructions. Sample reagent was added
in a 2:1 ratio to sputum in 15 ml falcon tube and the
tube was manually agitated twice during a 15 min-
incubation period at room temperature. Then 2 ml of
the inactivated material was transferred to the test car-
tridge by a sterile disposable pipette (provided with kits).
Cartridges were loaded into the Gene Xpert. At the end
of the real-time PCR run, the Xpert MTB/RIF assay’s
data analysis algorithm identified a specimen as MTB
positive if at least two of the five rpoB probes werepositive within two cycles of each other. Failure of one
or more of the rpoB-specific molecular beacons to hybri-
dize to the rpoB amplicon was interpreted as rifampin
resistance. Data interpretation was received after com-
pletion of the PCR run through computed software.
IV. Detection of rifampicin resistance: by the reference auto-
mated broth-based MGIT 960, the high-level rifampicin-
resistant strains (resistant to 250 lg/ml) and low-level
rifampicin-resistant strains (resistant to 50 lg/ml) were
detected. A 500 ll sample was inoculated in MGIT
960. After the culture flashed positive, streptomycin, iso-
niazid, rifampin and ethambutol (SIRE) MGIT-DST
were performed along with the manufacturer’s protocol.
Statistical analysis
Patient data, ZN smear results, culture findings, susceptibility
results of MGIT 960 and Xpert MTB/RIF PCR data were col-
lected, tabulated and analyzed using SPSS version 19 statistical
package. In the statistical analysis, frequencies, mean values
and percentages were presented. Odds ratio and chi-square
were used to compare variables. Sensitivity, specificity and
accuracy were calculated according to equations.
Results
Out of 58 patients (with age range 21–67 years) clinically sus-
pected to have pulmonary retreatment TB, Z–N smear exam-
ination was positive for AFB in 49 (90.7%). L–J Culture
results revealed positive yield in 54 cases. In addition to posi-
tive results for MTB, detection by Gene Xpert MTB/RIF was
in 54 of cases. The present study clarified that Gene Xpert
detected an extra positive retreatment tuberculosis case as
compared with culture on LJ media as the gold standard test.
It can detect more five positive TB cases when compared with
ZN microscopy indicating a higher sensitivity of 98.15%,
specificity was 75%. Another negative case was detected in
comparison with LJ culture. Thirty-seven isolates (68.5%)
were resistant to rifampicin by both MGIT 960 and Gene
Xpert MTB/RIF.
Discussion
After the WHO’s endorsement of Gene Xpert assay in 2010,
different research studies have been conducted to examine
Gene Xpert’s utility in different countries and populations.
Yet up to our knowledge, no sufficient data are available
regarding retreatment tuberculosis cases. As literature studies
were covering active cases of TB, MDR–TB, extrapulmonary
640 T.E. Meawed, A. ShakerTB (EPTB) or associated TB in HIV cases, nonetheless, this
study adheres sticky to retreatment cases as a challenging resis-
tant population to antituberculous treatment in Egyptian
communities.
Detection of retreatment cases of tuberculosis is essential
for National Control Program, nevertheless it is often con-
fronted by the limitation of transport and specimen storage
from other locations to the reference laboratory. Coupled with
underestimated case reporting owing to patient incompliance
either to history giving or regular visits for drug intake.
In the current study, sharp differentiation of patients into
clinical types could not be met, as a consequence of misleading
data offered by some patients. Diagnosis of retreatment cases
rested on comprehensiveness of clinicians, available medical
records and interpretation of patient history to attain mean-
ingful conclusions.
Xpert MTB/RIF assay is a double-edged weapon, indicates
the presence or absence of M. tuberculosis, in a semi quantita-
tive approximation of concentration and the presence or
absence of RIF resistance [9].
This work revealed that all smear positive specimens
showed positive yield on culture, and Gene Xpert MTB/RIF
assay’s results were positive (100%). It is evidenced that Gene
Xpert MTB/RIF can detect MTB in five out of the remaining
nine smear negative specimens.
ZN smear microscopy despite of being the available screen-
ing tool, it carries the risk of false negative results and incom-
petency to discriminate between drug susceptible and drug
resistant strains of MTB. These are owing to poor sample
quality coupled with a need for an experienced specialist.
Meanwhile, culture being the gold standard for detecting
MTB, proceeds for weeks up to months to yield results, and
depends on sophisticated laboratory facilities and skilled tech-
nicians [10,11].
The out performance of Xpert MTB/RIF detected in cur-
rent work is in agreement with other researchers who estab-
lished the diagnosis in a significant proportion of patients
and up to 10–15% of smear-negative TB [12,13]. Moreover,
another study confirmed up 49.7% relative gain and more case
detection by means of Xpert as an add-on test, recommending
performing Xpert as the first diagnostic test, to avoid extraor-
dinary work load [14].
Culture is regarded as the best available reference standard
for active TB disease and was the reference standard for TB in
most studies.
In the current study, culture on LJ medium stood as the
gold standard for detecting MTB. High sensitivity of Gene
Xpert MTB/RIF detected in the current study (98.15%) helps
to rule out disease with a high degree of confidence. Its accu-
racy was 96.55%.
A previous Egyptian study in a cohort of MTB patients
recorded that, the sensitivity of Xpert in detection of smear
positive, culture positive TB was 100% and in smear negative,
culture positive TB was 66.6% while its specificity in both was
100% [15].
Even with Versa TREK considered by El Hossary, as the
gold standard test, the author reported the superior sensitivity
of Gene Xpert MTB/RIF to detect MTB in smear positive
specimens compared to Versa TREK (100% versus 52.3%)
in Saudi Arabia [16].
Since 2010, the WHO recommended the Xpert MTB/RIF
(Cepheid) assay as a diagnostic tool, being reported in amulti-country study to have sensitivities of 98.2% among
smear-positive, culture positive patients and 72.5% among
smear negative, culture positive patients on a single direct
Xpert MTB/RIF test compared to repeated smears and culture
results [17]. Other researchers reported 100% sensitivity and
specificity of 86% [13], and 86.9% sensitivity and 99.7% speci-
ficity [18].
Xpert MTB/RIF assay did not cross-react with different
non-tuberculous mycobacteria (NTM) species tested at high
copy numbers, suggesting that the assay would have high speci-
ficity not affected by the presence of NTM species or cross-
contamination [4]. It is worth noting that Xpert MTB/RIF
requires minimal biosafety facilities, allowing sample decon-
tamination, hands-free operation, on-board sample processing.
It has a high sensitivity in smear-negative pulmonary TB and
ultrasensitive in hemi-nested PCR for smear positive [19].
The superiority of Gene Xpert MTB/RIF assay in retreat-
ment TB cases lies on its ability not only to detect TB bacilli,
but in forecasting treatment response to rifampicin as well.
A number of studies have raised concerns about rapid drug
susceptibility test (DST) methods, in particular automated
MGIT 960, for detection of rifampicin resistance [20].
This study showed a head-to-head comparison between
DST results of MGIT 960 as a reference test and Gene Xpert
MTB/RIF regarding rifampicin resistance led to equivalent
results of both. Rifampicin resistance was detected in 37
(68.5%) indicating that sensitivity and specificity of Gene
Xpert MTB/RIF were 100% each. Meanwhile sensitivity and
specificity of rifampin resistance in clinical specimens were
reported to range from 86% to 100% and 95% to 100%,
respectively, with higher sensitivity in smear-positive cases [6].
Moreover, the superiority of Xpert MTB/RIF was noticed
in identification of more cases with mutations to the rpoB gene
than which appeared to be rifampicin susceptible using MGIT
960 [21]. In addition to the lengthy average time required for
completion of the reference test MGIT was 2.5 days [22].
From current operational approach, on the basis of time
benefit analysis, Xpert MTB/RIF had the least turnaround
time, it took about two hours. On the other hand the less sen-
sitive screening tool, ZN smear consumed more time with false
negative results and/or double or triple specimens, meanwhile
the gold standard test used, LJ culture took about 4–8 weeks.
In agreement with our comment, it was recognized that Gene
Xpert testing may have improved detection and time to appro-
priate treatment for drug-resistant cases, thereby potentially
reducing transmission of drug-resistant disease [23].
To sum up, this study highlighted the realistic accuracy of
Gene Xpert MTB/RIF assay’s sensitivity of 98.15%, specificity
of 75% and accuracy of 96.55% in MTB diagnosis. Coupled
with absolute sensitivity and specificity 100% each for detec-
tion of MTB rifampicin resistance by MGIT. Gene Xpert
MTB/RIF should be integrated in diagnostic approach to
improve the understanding of the retreatment TB cases.
Finally the authors recommend restandardization of reference
test with Gene Xpert MTB/RIF to obtain more valid results.Limitations
Inaccurate history giving of retreatment patients and insuffi-
cient documentation in post-discharge file reviews led to
underestimated case reporting and relatively small size.
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